These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12802797)

  • 21. Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
    Yuuki S; Komatsu Y; Fuse N; Kato T; Miyagishima T; Kudo M; Watanabe M; Tateyama M; Kunieda Y; Wakahama O; Sakata Y; Asaka M
    Clin Drug Investig; 2010; 30(4):243-9. PubMed ID: 20225907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
    Tai CJ; Liu JH; Chen WS; Lin JK; Wang WS; Yen CC; Chiou TJ; Chen PM
    Jpn J Clin Oncol; 2003 Mar; 33(3):136-40. PubMed ID: 12672791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
    Hwang JJ
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy].
    Aiba K
    Gan To Kagaku Ryoho; 2004 May; 31(5):706-11. PubMed ID: 15170977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
    Goldberg RM
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):21-8. PubMed ID: 9786313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
    Kouroussis C; Souglakos J; Mavroudis D; Papadouris S; Kakolyris S; Agelaki S; Kalbakis K; Panopoulos C; Vardakis N; Sarra E; Georgoulias V
    Am J Clin Oncol; 2002 Dec; 25(6):627-31. PubMed ID: 12478014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing the use of irinotecan in colorectal cancer.
    Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
    Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
    Douillard JY;
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):51-5. PubMed ID: 11200150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Kummar S; Copur MS; Rose M; Wadler S; Stephenson J; O'Rourke M; Brenckman W; Tilton R; Liu SH; Jiang Z; Su T; Cheng YC; Chu E
    Clin Colorectal Cancer; 2011 Jun; 10(2):85-96. PubMed ID: 21859559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Fisher MD
    Clin Colorectal Cancer; 2001 Aug; 1(2):85-6. PubMed ID: 12445365
    [No Abstract]   [Full Text] [Related]  

  • 32. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Benson AB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
    Kalofonos HP; Papakostas P; Makatsoris T; Papamichael D; Vourli G; Xanthakis I; Aravantinos G; Papadimitriou C; Pentheroudakis G; Varthalitis I; Samelis G; Syrigos KN; Xiros N; Stavropoulos M; Kosmidis P; Christodoulou C; Linardou H; Skondra M; Pectasides D; Economopoulos T; Fountzilas G
    Anticancer Res; 2010 Oct; 30(10):4325-33. PubMed ID: 21036759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreasing dosage of irinotecan, 5-flurouracil (5-FU) and leucovorin (LV) in the treatment of advanced and/or metastatic colorectal cancer: a phase II study.
    Huang JS; Yen CL; You YT; Wang CH; Lan YJ; Lai CH; Chueh TC; Liaw CC
    Chang Gung Med J; 2006; 29(3):297-305. PubMed ID: 16924892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
    Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
    Hartmann JT; Oechsle K; Jäger E; Reis HE; Haag C; Niederle N; Wilke HJ; Pflüger KH; Batran SA; Büchele T; Hofheinz RD; Kanz L; Bokemeyer C
    Anticancer Drugs; 2004 Jun; 15(5):473-7. PubMed ID: 15166621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
    André T; Louvet C; Maindrault-Goebel F; Couteau C; Mabro M; Lotz JP; Gilles-Amar V; Krulik M; Carola E; Izrael V; de Gramont A
    Eur J Cancer; 1999 Sep; 35(9):1343-7. PubMed ID: 10658525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
    J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of the role of CPT-11 in the treatment of colorectal cancer.
    Rougier P; Mitry E
    Clin Colorectal Cancer; 2001 Aug; 1(2):87-94. PubMed ID: 12445366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.